Fulcrum Therapeutics Inc. (FULC) Announces Interim Analysis Data from its ReDUX4 Trial in FSHD

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/22/2026

1. USO
2. META
3. NVDA
4. DCOY
5. SPY
6. MSFT
7. VKTX
8. PRGS
9. CMPX
10. GS

Go back to Fulcrum Therapeutics Inc. (FULC) Announces Interim Analysis Data from its ReDUX4 Trial in FSHD

Fulcrum Therapeutics Announces Interim Analysis Data from its ReDUX4 Trial in Facioscapulohumeral Muscular Dystrophy (FSHD)

August 11, 2020 7:01 AM EDT

Reduction in DUX4-driven gene expression observed in biopsies with highest baseline levels of DUX4-driven gene expression

Topline data on-track for Q1 2021 with full data in Q2 2021

Company to review clinical data on second quarter earnings call today at 8:00am ET

CAMBRIDGE, Mass., Aug. 11, 2020 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq:... More